CLVS News and Press, Clovis Oncology Inc. From 04/25/22

Clovis, a "trading stock," has some shakiness in its fundamentals. Moreover, the shares tend to rise and fall for you to trade for short-term gains. Due to upcoming catalysts in June, Clovis is a trading stock that is about to embark on another bullish cycle. Despite being a tradi...

An early April surge in the share price of Clovis Oncology (NASDAQ:CLVS) following positive late-stage data on Rubraca (rucaparib) for ovarian cancer is gone. Since March 31 -- the date the late-stage results were announced -- through April 22, shares are up 7%. However, from March 31 th...

Palm Beach, FL – April 25, 2022 – FinancialNewsMedia.com News Commentary – The formation of mutational cells or tissues in female reproductive organs called ovaries leads to ovarian cancer. Cancer remains undetected until the mutation spreads to the stomach ...

Clovis Oncology, Inc. (NASDAQ: CLVS) will announce its first quarter 2022 financial results on Wednesday, May 4, 2022, before the open of the US financial markets. Clovis’ senior management will host a conference call and live audio webcast at 8:30am ET to discuss the Company...

It was a strange day for Clovis Oncology (NASDAQ: CLVS) as the stock dropped 10.5% early in the day, only to close the day higher than it opened. The stock closed at $2.28 on Thursday but opened at $2.13 per share on Monday. It fell to as low as $2.04 in the early morning hours befo...

Palm Beach, FL – April 14, 2022 – FinancialNewsMedia.com News Commentary – CAR-T therapy is a sort of treatment in which a patient’s T cells which is a type of immune system cell, are genetically modified to attack cancer cells in the lab. T cells are...

The market recently discounted ImmunoGen due to its expectation of Mirvetuximab's SORAYA data. Contrary to market belief, I view Mirve as a stellar drug for the treatment of advanced ovarian cancer. I forecast a high likelihood of upcoming Mirve approval. For further details...

Analyses of non-clinical study data demonstrate longer tumor retention with 177 Lu-FAP-2286 than 177 Lu-FAPI-46, resulting in greater tumor inhibition Phase 1 data is expected later this year from the ongoing LuMIERE clinical trial evaluating FAP-2286 as a therapeuti...

3 Penny Stocks For Your Watchlist After a Bearish Trading Day There’s a lot of debate surrounding penny stocks – whether they’re actually worth investing in, or if they’re just an easy way to make quick money. So, what’s the verdict? Are penny stocks...

The commercial-stage biotech Clovis Oncology (CLVS +9.0%) continues to trade higher on Monday extending the recent rally to third consecutive session following the positive late-stage results announced by the company last week for Rubraca in ovarian cancer. The announcement that the monothera...